This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
AOC 1020 has been designed for the treatment of the underlying cause of FSHD, which is caused by the abnormal expression of a gene known as double homeobox 4 or DUX4. Avidity Biosciences’ AOC 1020 is intended to reduce the DUX4 mRNA and DUX4 proteinexpression in muscles in these patients.
In mice, an antibody directed against this factor was able to slow the growth of metastatic tumors.Blood vessels produce growth factor that promotes metastases. ” With a particular focus on the lung, the researchers performed global geneexpression analyses of the metastatic niche.
Adeno-associated virus vectors, alcohol dehydrogenase compositions, and antibody serum stabilisers are some of the accelerating innovation areas, where adoption has been steadily increasing. Among maturing innovation areas are anti-influenza antibody compositions and anti-interleukin-1, which are now well established in the industry.
Coding RNAs include messenger RNA (mRNA) and short interfering RNA (siRNA), which encode proteins and silence geneexpression, respectively. ASOs are short single-stranded nucleotides that bind to specific messenger RNAs and prevent the production of a particular protein.
The biotech acquisition will also see Takeda getting Maverick’s TAK-280 (MVC-280), an immunotherapy designed to treat patients with B7H3-expressing solid tumors which is expected to enter the clinic later this year. The biotech acquisition deal includes Five Prime’s prime asset bemarituzumab, which is a first-in-class anti-FGFR2b antibody.
HDACs catalyze the removal of acetyl groups from acetylated lysine residues in histones, resulting in the modulation of geneexpression. HDACs also deacetylate non-histone proteins, such as transcription factors. Reactivation of hepatitis B virus infection was reported in 1% of patients in clinical trials.
Roche bets USD 120 Million on UCB’s anti-tau Alzheimer’s antibody. The Swiss pharma, Roche, is handing over USD 120 million upfront for the right of UCB’s anti-tau antibody development. Omega’s platform is designed to adjust geneexpression to healthy levels rather than switching genes on and off.
Vir Biotechnology and GlaxoSmithKline dosed the first patient in a new sub-trial of a Phase III study of monoclonal antibody VIR-7831 for hospitalized adults with COVID-19. The drug is a humanized IgG4 monoclonal antibody that blocks CCR5 and is being developed for COVID-19, HIV and metastatic triple-negative breast cancer.
SARS-CoV-2 is characterized by an outer surface speckled with spike proteins, giving it a crown-like appearance, hence the name “corona,” which is the Latin word for crown. The spike protein is critical for binding to ACE2 receptors on host cells — this interaction mediates the entry of the virus into cells. Drug Approvals.
We organize all of the trending information in your field so you don't have to. Join 21,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content